SINTILIMAB

PD-1 INHIBITOR

Lilly

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.



MHC can be MHC I or MHC II

Agata Y, et al[1]; Ishida Y, et al[2]; Marin-Acevedo JA, et al[3]; Chen L and Flies DB[4]

TARGET

The interaction of programmed cell death protein 1 (PD-1) transmembrane protein receptor, which is found in lymphocytes and monocytes, with its natural ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), is one of the major pathways exploited by cancer cells for immune evasion.[1-3] The PD-1/ligand interactions strongly counteract T-cell antigen receptor (TCR) signal transduction and subsequently attenuate cytokine production, T-cell survival, and proliferation.[4]

MOLECULE

Sintilimab is a recombinant, fully human anti–PD-1 monoclonal antibody that has been shown in preclinical studies to bind to PD-1 and block interactions between PD-1 and PD-L1/PD-L2 to restore antitumor immunity.[5] Sintilimab enhances T-cell function, including antitumor responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells.[5,6]

CLINICAL DEVELOPMENT

Sintilimab is being investigated in a clinical trial in patients with non-small cell lung cancer.

References: 1. Agata Y, et al. *Int Immunol*. 1996;8(5):765-772. **2.** Ishida Y, et al. *EMBO J*. 1992;11(11):3887-3895. **3.** Marin-Acevedo JA, et al. *J Hematol Oncol*. 2018;11(1):39. **4.** Chen L, Flies DB. *Nat Rev Immunol*. 2013;13(4):227-242. **5.** Wang J, et al. *MAbs*. 2019;11(8):1443-1451. **6.** Zhang S, et al. *Antib Ther*. 2018;1:65-73.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

ACTIVE TRIAL CURRENTLY NOT ENROLLING

[NCT03607539] Lung Cancer
ORIENT-11: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Nonsquamous NSCLC

Pipeline information is current through April 28, 2022.

VV-OTHR-US-DEL-0828 04/2022 PRINTED IN USA